Aytu Biopharma climbs on FDA "fast track" tag for rare genetic therapy

Aytu Biopharma

19/04/2022 14:17

** Aytu Biopharma's  AYTU.O  shares up 20.4% to $1.1
premarket 
    ** Drugmaker says the U.S. FDA has granted fast track
designation to its drug candidate, AR101, for treating Vascular
Ehlers-Danlos Syndrome (VEDS)  urn:newsml:reuters.com:*:nACSmT3HVa
    ** The tag is intended to speed up development and review of
therapeutics intended to treat serious or life-threatening
conditions
    ** AYTU adds it can initiate its clinical trial as quickly
as possible, with plans to begin patient dosing by late 2022 or
early 2023
    ** VEDS is a more severe form of Ehlers-Danlos syndrome, a
group of inherited disorders that affects connective tissues
including in the skin, joints and blood vessel walls; VEDS can
cause the walls of blood vessels, intestines or uterus to
rupture 
    ** About 13.4 mln shares of the Englewood, Colorado-based
company have traded so far, about 64 times their 30-DMA volume
    ** As of last close, stock had fallen 30.8% YTD

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))